You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
西藏药业(600211.SH)拟斥3.4亿人币购买上海临港房地产进行疫苗生产线建设
阿思达克 09-08 07:45
西藏药业(600211.SH)公布,为疫苗生产需要,公司拟向上海临港华平经济发展有限公司购买位於上海市临港奉贤园区临港智造园六期项目的房地产进行生产线建设。

第一期拟购买房屋建筑面积约2.74万平方米,每平方米单价约10,500元人民币(下同),合计约2.88亿元,相关房屋买卖合同尚未签署;第二期拟购买土地约70亩,具体将视项目推进情况另行协商。该房屋和土地预计总金额约3.4亿元。

公司表示,公司与斯微生物进行合作研发,仅获得相关疫苗的商业化权利等,公司不成为相关疫苗的权益所有人。相关疫苗尚未取得临床批件,处於临床前研究阶段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account